Mechanisms Governing Metastatic Dormancy and Reactivation

Overview

Journal Cell

Publisher Cell Press

Specialty Cell Biology

Date 2013 Nov 12

PMID 24209616

Citations 308

Authors

Filippo G Giancotti

Affiliations

Soon will be listed here.

Abstract

Many cancer patients suffer from metastatic relapse several years after they have undergone radical surgery. Early cancer cell dissemination followed by a protracted period of dormancy potentially explains this prevalent clinical behavior. Increasing evidence suggests that the metastasis-initiating cells are cancer stem cells or revert to this functional state upon infiltrating a target organ. Their entry into dormancy and subsequent reactivation are governed by intrinsic programs and by contextual cues, which resemble those regulating the self-renewal capability of adult stem cells. In addition, metastatic cells undergoing reactivation are nursed by specialized extracellular matrix niches, which support positive signals, such as Wnt and Notch, and attenuate negative signals, such as BMP. In spite of significant remaining uncertainties, these findings provide a framework to understand the logic of metastatic dormancy and reactivation and open new avenues for therapeutic intervention.

Citing Articles

Integrating model systems and genomic insights to decipher mechanisms of cancer metastasis.

Leung M, Swanton C, McGranahan N Nat Rev Genet. 2025; .

PMID: 40065153 DOI: 10.1038/s41576-025-00825-2.

How modulation of the tumor microenvironment drives cancer immune escape dynamics.

Shrestha P, Ghoreyshi Z, George J Sci Rep. 2025; 15(1):7308.

PMID: 40025156 PMC: 11873109. DOI: 10.1038/s41598-025-91396-z.

Invasion and metastasis in cancer: molecular insights and therapeutic targets.

Li Y, Liu F, Cai Q, Deng L, OuYang Q, Zhang X Signal Transduct Target Ther. 2025; 10(1):57.

PMID: 39979279 PMC: 11842613. DOI: 10.1038/s41392-025-02148-4.

Towards understanding cancer dormancy over strategic hitching up mechanisms to technologies.

Yang S, Seo J, Choi J, Kim S, Kuk Y, Park K Mol Cancer. 2025; 24(1):47.

PMID: 39953555 PMC: 11829473. DOI: 10.1186/s12943-025-02250-9.

Statins as Secondary Preventive Agent to Limit Breast Cancer Metastatic Outgrowth.

Atale N, Wells A Int J Mol Sci. 2025; 26(3).

PMID: 39941069 PMC: 11818786. DOI: 10.3390/ijms26031300.

References

Tavazoie S, Alarcon C, Oskarsson T, Padua D, Wang Q, Bos P . Endogenous human microRNAs that suppress breast cancer metastasis. Nature. 2008; 451(7175):147-52. PMC: 2782491. DOI: 10.1038/nature06487. View

Levental K, Yu H, Kass L, Lakins J, Egeblad M, Erler J . Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell. 2009; 139(5):891-906. PMC: 2788004. DOI: 10.1016/j.cell.2009.10.027. View

Korpal M, Ell B, Buffa F, Ibrahim T, Blanco M, Celia-Terrassa T . Direct targeting of Sec23a by miR-200s influences cancer cell secretome and promotes metastatic colonization. Nat Med. 2011; 17(9):1101-8. PMC: 3169707. DOI: 10.1038/nm.2401. View

Campbell P, Yachida S, Mudie L, Stephens P, Pleasance E, Stebbings L . The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature. 2010; 467(7319):1109-13. PMC: 3137369. DOI: 10.1038/nature09460. View

Baylin S, Jones P . A decade of exploring the cancer epigenome - biological and translational implications. Nat Rev Cancer. 2011; 11(10):726-34. PMC: 3307543. DOI: 10.1038/nrc3130. View

Gao H, Chakraborty G, Lee-Lim A, Mo Q, Decker M, Vonica A . The BMP inhibitor Coco reactivates breast cancer cells at lung metastatic sites. Cell. 2012; 150(4):764-79. PMC: 3711709. DOI: 10.1016/j.cell.2012.06.035. View

Kobayashi A, Okuda H, Xing F, Pandey P, Watabe M, Hirota S . Bone morphogenetic protein 7 in dormancy and metastasis of prostate cancer stem-like cells in bone. J Exp Med. 2011; 208(13):2641-55. PMC: 3244043. DOI: 10.1084/jem.20110840. View

Aguirre-Ghiso J . Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer. 2007; 7(11):834-46. PMC: 2519109. DOI: 10.1038/nrc2256. View

Ocana O, Corcoles R, Fabra A, Moreno-Bueno G, Acloque H, Vega S . Metastatic colonization requires the repression of the epithelial-mesenchymal transition inducer Prrx1. Cancer Cell. 2012; 22(6):709-24. DOI: 10.1016/j.ccr.2012.10.012. View

10.

Mani S, Guo W, Liao M, Eaton E, Ayyanan A, Zhou A . The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008; 133(4):704-15. PMC: 2728032. DOI: 10.1016/j.cell.2008.03.027. View

11.

Gupta G, Perk J, Acharyya S, de Candia P, Mittal V, Todorova-Manova K . ID genes mediate tumor reinitiation during breast cancer lung metastasis. Proc Natl Acad Sci U S A. 2007; 104(49):19506-11. PMC: 2148319. DOI: 10.1073/pnas.0709185104. View

12.

Sneddon J, Werb Z . Location, location, location: the cancer stem cell niche. Cell Stem Cell. 2008; 1(6):607-11. PMC: 2571117. DOI: 10.1016/j.stem.2007.11.009. View

13.

Mazzieri R, Pucci F, Moi D, Zonari E, Ranghetti A, Berti A . Targeting the ANG2/TIE2 axis inhibits tumor growth and metastasis by impairing angiogenesis and disabling rebounds of proangiogenic myeloid cells. Cancer Cell. 2011; 19(4):512-26. DOI: 10.1016/j.ccr.2011.02.005. View

14.

Van Zee K, Linkov I, Borgen P, Gerald W . Biological behavior of human breast cancer micrometastases. Clin Cancer Res. 2001; 7(8):2434-9. View

15.

Chen Q, Zhang X, Massague J . Macrophage binding to receptor VCAM-1 transmits survival signals in breast cancer cells that invade the lungs. Cancer Cell. 2011; 20(4):538-49. PMC: 3293160. DOI: 10.1016/j.ccr.2011.08.025. View

16.

Morrison S, Spradling A . Stem cells and niches: mechanisms that promote stem cell maintenance throughout life. Cell. 2008; 132(4):598-611. PMC: 4505728. DOI: 10.1016/j.cell.2008.01.038. View

17.

McAllister S, Gifford A, Greiner A, Kelleher S, Saelzler M, Ince T . Systemic endocrine instigation of indolent tumor growth requires osteopontin. Cell. 2008; 133(6):994-1005. PMC: 4121664. DOI: 10.1016/j.cell.2008.04.045. View

18.

Wu X, Northcott P, Dubuc A, Dupuy A, Shih D, Witt H . Clonal selection drives genetic divergence of metastatic medulloblastoma. Nature. 2012; 482(7386):529-33. PMC: 3288636. DOI: 10.1038/nature10825. View

19.

Tsao H, Cosimi A, Sober A . Ultra-late recurrence (15 years or longer) of cutaneous melanoma. Cancer. 1997; 79(12):2361-70. View

20.

Freedland S, Moul J . Prostate specific antigen recurrence after definitive therapy. J Urol. 2007; 177(6):1985-91. DOI: 10.1016/j.juro.2007.01.137. View